Annual rank45
Belgium · Healthcare
Ucb
Focuses on creating solutions intended to improve life for people living with neurological and autoimmune conditions.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Medicines, research platforms and supply for severe diseases
UCB is a Belgian biopharmaceutical group focused on severe neurological and immune-mediated diseases. Its portfolio spans epilepsy, rare neurological conditions, myasthenia gravis, inflammatory disease and osteoporosis. Behind those medicines is a research system working across antibodies, peptides, small molecules, drug-device combinations and gene therapy, supported by clinical-study infrastructure and manufacturing sites in Europe, Japan and the United States.
Neurology medicines
Different formats for epilepsy and rare neurological disease
UCB's neurology portfolio includes Briviact for focal seizures and Fintepla for seizures associated with Dravet and Lennox-Gastaut syndromes. Rystiggo and Zilbrysq address defined forms of generalised myasthenia gravis through different active substances; availability and approved uses vary by country.
- Medicine directory The complete UCB list with diseases and country-specific information
- Briviact Brivaracetam and its approved epilepsy settings
- Fintepla Fenfluramine for Dravet and Lennox-Gastaut syndromes
- Rystiggo Rozanolixizumab in generalised myasthenia gravis
- Zilbrysq Zilucoplan in generalised myasthenia gravis
Immunology and bone health
One portfolio crosses skin, joints, bowel and bone
Bimzelx is listed for conditions including plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa. Cimzia is used across several inflammatory conditions, while Evenity sits in osteoporosis. UCB's disease page explains why the immunology business is organised around connected inflammatory pathways rather than a single diagnosis.
- Bimzelx Bimekizumab and its approved inflammatory-disease settings
- Cimzia An example of certolizumab pegol across inflammatory disease
- Evenity Romosozumab in osteoporosis
- Immunology at UCB The disease areas and portfolio logic behind the medicines
Discovery and development
From macrocyclic peptides to drug-device combinations
UCB's discovery toolkit includes small molecules, monoclonal antibodies, AAV vectors and the ExtremeDiversity platform for synthetic macrocyclic peptides. Its pipeline applies those modalities to programmes such as dapirolizumab pegol, bepranemab, glovadalen, galvokimig and STACCATO alprazolam; the clinical-study library shows how programmes are tested and disclosed.
- Clinical pipeline Named assets, modalities, indications and development stages
- Drug-discovery platforms Small molecules, antibodies, peptides and AAV vectors
- Clinical studies at UCB Study transparency, registries and the development process
- ▶ VideoWatch: how medicines are tested UCB's English overview of the clinical-study journey
Research, supply and lived experience
A network that connects laboratories, plants and patients
Braine-l'Alleud combines research and manufacturing, Bulle brings biotechnology and chemical production together, and UCB has added a gene-therapy pilot plant in Belgium while planning biologics capacity in Georgia. The Faces of MG project places this infrastructure beside first-person accounts of living with myasthenia gravis.
- Global R&D locations Research and manufacturing roles from Belgium to Japan and the US
- Braine biotechnology plant The site's shift from small molecules towards biologics
- Inside the gene-therapy facility A 1,200-square-metre clinical manufacturing pilot plant
- Georgia manufacturing project Planned US biologics capacity, automation and local skills
- Faces of MG Photography and first-person stories about myasthenia gravis
Official profile sources: About UCB | UCB · UCB Further Facts & Figures · UCB Integrated Annual Report 2025
Current 2026 update
What has changed in 2026?
Clinical-data update on 8 July 2026 · 8 July 2026
Clinical-data update on 8 July 2026latest official update
4company-specific highlights
+4%2026 stock return · context only
Rozanolixizumab cycle data
Pooled data from 129 adults indicated symptom improvements across repeated rozanolixizumab treatment cycles in generalized myasthenia gravis.
Zilucoplan pen usability
In a mixed study group of patients, caregivers and healthcare professionals, 90 of 100 participants successfully performed a first injection without prior training.
Zilucoplan long-term data
The reported long-term data showed clinical benefits with zilucoplan sustained through week 120.
MuSK-Ab+ safety observations
In the 18 MuSK-Ab+ patients with at least one treatment cycle, 14 (77.8%) reported treatment-emergent adverse events; most were mild or moderate.
Official 2026 sources: UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026 · 8 July 2026
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 45 | +40% | +273% | +236% |